Kidney problems can lead to reduced kidney function and, in severe cases, kidney failure, requiring dialysis or a kidney transplant
L.HuL.et al (2017)
Recently, it has gained attention as a potential intervention for various neurological and neurodevelopmental disorders, including ASD
Why Glucagon Receptor Agonism Adds Value The addition of glucagon receptor activation to the GIP/GLP-1 backbone introduces several theoretical advantages: Increased energy expenditure: Glucagon receptor activation promotes hepatic glycogenolysis and gluconeogenesis and may increase resting metabolic rate, addressing one of the key limitations of incretin-based therapy where metabolic adaptation can slow weight loss over time Hepatic fat reduction: Glucagon signaling promotes hepatic lipid oxidation, which may provide superior benefits for patients with metabolic dysfunction-associated steatohepatitis (MASH) Preserved lean mass: Early data suggest that the increased energy expenditure from glucagon agonism may help preserve lean body mass during weight loss, though this requires confirmation in larger trials Clinical Implications for Current Practice While retatrutide is not yet FDA-approved, providers should be aware of its development as it will likely reshape the obesity pharmacotherapy landscape upon approval
Potential concerns include effects on infant appetite regulation, pancreatic development, or metabolic programming, but these remain theoretical without direct evidence
